The U.S. Department of Commerce’s Bureau of Industry and Security updated the Export Administration Regulations to designate 32 new entities including three Chinese biotechnology companies—Beijing Tianyi Huiyuan Biotechnology, Beijing Tsingke Biotech, and Sangon Biotech (Shanghai). These firms are implicated in risky activities potentially benefiting China's military medical research. New licensing requirements with a presumption of denial apply to exports to these firms, reflecting escalating U.S. trade restrictions amid ongoing diplomatic tensions.